Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$172.06
+2.7%
$155.31
$111.09
$183.00
$10.49B0.41494,883 shs1.18 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.61
+2.1%
$29.52
$23.15
$170.47
$10.67B1.997.42 million shs7.54 million shs
Merus stock logo
MRUS
Merus
$44.19
-2.8%
$43.96
$33.19
$61.61
$3.14B0.94712,091 shs705,630 shs
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$14.00
+1.2%
$13.23
$12.26
$16.89
$11.69B0.511.48 million shs1.24 million shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+4.82%+14.64%+31.69%+22.02%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+1.43%+7.31%-29.96%-75.23%
Merus stock logo
MRUS
Merus
0.00%+1.42%+5.90%+7.94%-6.02%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.00%+1.38%+5.78%+1.19%-5.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.1321 of 5 stars
3.52.00.00.02.11.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.4084 of 5 stars
4.01.00.04.62.42.51.3
Merus stock logo
MRUS
Merus
3.3732 of 5 stars
4.63.00.00.03.81.70.0
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
1.6417 of 5 stars
2.32.01.70.02.80.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.93
Moderate Buy$211.4022.86% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$53.9595.39% Upside
Merus stock logo
MRUS
Merus
3.13
Buy$85.3193.05% Upside
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.50
Moderate Buy$17.0021.43% Upside

Current Analyst Ratings Breakdown

Latest MRUS, RDY, MRNA, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$50.00 ➝ $32.00
4/28/2025
Merus stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/17/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/16/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$205.00
(Data available from 5/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$363.64M28.85N/AN/A($1.88) per share-91.52
Moderna, Inc. stock logo
MRNA
Moderna
$3.14B3.40N/AN/A$28.33 per share0.97
Merus stock logo
MRUS
Merus
$36.13M84.61N/AN/A$6.17 per share7.16
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$311.31B0.04$1.06 per share13.25$4.50 per share3.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$7.10N/A716.92N/A-104.54%N/A-39.23%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-110.04%-28.74%-21.83%N/A
Merus stock logo
MRUS
Merus
-$154.94M-$3.27N/AN/AN/A-680.61%-38.89%-31.16%5/6/2025 (Estimated)
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$668M$0.6322.2917.07N/A17.25%17.87%12.32%5/6/2025 (Estimated)

Latest MRUS, RDY, MRNA, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Merus stock logo
MRUS
Merus
-$1.17N/AN/AN/AN/AN/A
5/6/2025Q4 24/25
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.20N/AN/AN/A$83.70 billionN/A
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
2/27/2025Q4 2024
Merus stock logo
MRUS
Merus
-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 million
2/12/2025Q4 2024
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.32-$0.68+$0.64-$0.68$115.06 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Merus stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.080.57%N/A12.70%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.17
0.84
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Merus stock logo
MRUS
Merus
N/A
8.32
8.32
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.02
1.92
1.38

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Merus stock logo
MRUS
Merus
96.14%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
3.85%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Merus stock logo
MRUS
Merus
4.57%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
64060.97 million36.41 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Merus stock logo
MRUS
Merus
3769.18 million65.34 millionOptionable
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
24,800834.77 million818.05 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$172.06 +4.59 (+2.74%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$172.00 -0.06 (-0.03%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.61 +0.58 (+2.15%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$27.48 -0.13 (-0.49%)
As of 05/2/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Merus stock logo

Merus NASDAQ:MRUS

$44.19 -1.26 (-2.77%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$46.32 +2.13 (+4.82%)
As of 05/2/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$14.00 +0.17 (+1.23%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$14.01 +0.01 (+0.10%)
As of 05/2/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.